NCT05615792: OCCP-HP

Observational Cohort of COVID-19 Patients in Hubei Province

Completed Last updated 7 March 2024

What this trial tests

trial testing No intervention in 2019 Novel Coronavirus Disease in 68,000 participants. Completed in 1 March 2024.

Timeline

1 February 2020

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	Dao Wen Wang
Status	Completed
Study type	OBSERVATIONAL
Enrollment	68,000
Start date	1 February 2020
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	1 location across China

Drugs / interventions tested

• No intervention

Conditions studied

• 2019 Novel Coronavirus Disease — all drugs for 2019 Novel Coronavirus Disease →

Sponsor

Dao Wen Wang — full company profile →

Who can join

18 and older, any sex, with 2019 Novel Coronavirus Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to use the relevant case data of COVID-19 in Hubei Province, using big data processing and mining methods to evaluate the effects of clinical indicators, drug use and genes on the clinical prognosis of COVID-19 patients, so as to provide a theoretical basis for the treatment of these diseases and reduce the mortality.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic: new perspectives and insights.
   He W, Xu K, Ni L, Wu J, et al · · 2023 · cited 6× · PMID 37839550 · DOI 10.1016/j.virs.2023.10.005
2. NT-proBNP ratio is a potential predictor for COVID-19 outcomes in adult Chinese patients: a retrospective study.
   Li D, He W, Yu B, Wang DW, et al · · 2024 · cited 4× · PMID 38467760 · DOI 10.1038/s41598-024-56329-2
3. Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study from 2019 to 2020 in China.
   Xu K, He W, Yu B, Zhong K, et al · · 2025 · cited 4× · PMID 37566218 · DOI 10.1007/s10557-023-07494-5
4. Clinical characteristics and risk factors for in-hospital mortality of COVID-19 patients in Hubei Province: A multicenter retrospective study.
   He W, Li G, Xu K, Yu B, et al · · 2025 · cited 1× · PMID 39687686 · DOI 10.1016/j.ijcha.2024.101574
5. Beneficial effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: a Retrospective Study from 2019 to 2020 in China
   Xu K, He W, Yu B, Zhong K, et al · · 2023 · cited 1× · DOI 10.21203/rs.3.rs-2930798/v1
6. The Counter-Regulatory Renin-Angiotensin System: A Surprising Ally in the Field of COVID-19.
   Palacios-Cruz M, Castellar-Lopez J, Pretelt JM, Chang AY, et al · · 2025 · PMID 40754875 · DOI 10.2174/0118715265352715250717101135
7. A Superior Prognostic Indicator for In-Hospital Mortality of Adult COVID-19 Patients
   Li D, He W, Wang DW, Ni L. · · 2023 · DOI 10.21203/rs.3.rs-3492666/v1